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Background: Cystic ﬁbrosis is caused by mutations in the cystic ﬁbrosis transmembrane conductance regulator (CFTR) gene. Over 1800 CFTR
mutations have been reported, and about 12% of mutations are believed to impair pre-mRNA splicing. Given that several synthetic, non-splice-
junction synonymous substitutions have been reported to alter splicing in CFTR, we predicted that naturally occurring synonymous substitutions
may be erroneously classiﬁed as functionally neutral.
Methods: Computational tools were used to predict the effect of synonymous substitutions on CFTR pre-mRNA splicing. The functional
consequences of selected substitutions were evaluated using a minigene splicing assay.
Results: Two synonymous mutations were shown to have a dramatic effect on CFTR pre-mRNA splicing, and consequently could alter protein
integrity and phenotypic outcome.
Conclusions: Traditional methods of mutation analysis overlook splicing defects that occur at internal positions in coding exons, especially
synonymous substitutions. We show that bioinformatics tools and minigene splicing assays are a potent combination to prioritize and identify
mutations that cause aberrant CFTR pre-mRNA splicing.
Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Synonymous substitution; Exon skipping; Minigene assay; SplicePort predictions; Ectopic splice sites1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene, which encodes a cAMP-regulated chloride
channel protein. Clinical manifestations of the disorder include
lung disease, pancreatic insufficiency, male infertility, and elevated
concentrations of chloride in sweat [1]. Severity of the disease is
highly variable and some patients demonstrate only a subset of the
classic CF symptoms [2]. Despite the phenotypic variability, CF is
most often caused by the ΔF508 mutation, which accounts for⁎ Corresponding author at: 5625 Fishers Lane, Rockville, MD 20852, USA.
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doi:10.1016/j.jcf.2012.04.009about 70% of mutant alleles among CF patients. This mutation,
which is located in the NBD1 domain, impairs processing of the
CFTR protein in the endoplasmic reticulum [3]. In total, 1877
mutations appear in the Cystic Fibrosis Mutation Database [4], and
226 (12%) of these mutations are implicated in pre-mRNA
splicing.
Mutations that interfere with accurate pre-mRNA splicing occur
at acceptor and donor splice sites (SSs), the branch point sequence,
and the polypyrimidine tract. Additionally, mutations can readily
disrupt regulated splicing by interfering with exonic splicing
regulators (ESRs) [5,6]. Such regulatory elements function as
exonic or intronic splicing enhancers (ESEs and ISEs, respectively)
or as exonic or intronic splicing silencers (ESSs and ISSs,
respectively). Regardless of their type (nonsense, missense, or
synonymous), substitutions can interfere with these internal
splicing regulatory elements, causing a variety of outcomes,ystic Fibrosis Society.
Table 1
Summary information for the variants chosen for experimental testing with the
minigene splicing assay.
Variant
number
rsSNP ID cDNA
name
Position on
chromosome
7
CFTR
Exon
#
Exon
size
(bps)
Position
within
exon
1 rs35033453 c.738GNA⁎ 116,962,696 6 164 159
2 rs1800083 c.915CNT 116,967,435 8 247 46
3 rs1800084 c.927CNG 116,967,447 8 247 58
4 rs1800105 c.2604ANG 117,022,333 15 129 114
5 rs1800122 c.3594GNT 117,054,937 22 249 126
Notes: ⁎This mutation (rs35033453) is not currently included in the CF
Mutation Database, but its corresponding cDNA name was determined based on
its position. The cDNA names for all mutations include the reference and
variant alleles observed at the corresponding locus. Genomic positions and
variant information of all mutations are relative to the reference strand of the
hg18 UCSC assembly of the human genome.
512 A. Scott et al. / Journal of Cystic Fibrosis 11 (2012) 511–517which include exon skipping, inclusion of intron sequences, or
activation of cryptic SSs [7]. These events could ultimately
produce unstable transcripts or defective protein isoforms, as
illustrated by splicing mutations in CF [8–11], breast cancer [12],
and ataxia telangiectasia [13].
The Cystic Fibrosis Mutation Database lists 226 mutations
implicated in CFTR splicing. Among these, five are exonic
synonymous substitutions. All five changes involve a GNA
substitution at the last nucleotide of the exon and disrupt splicing
by interfering with the donor SS. All other synonymous sub-
stitutions in the CFTR Mutation Database are classified as
polymorphisms, a fact that illustrates the common practice of
overlooking synonymous substitutions in clinical diagnostics,
because they are assumed to be functionally neutral. However,
about 25% of synonymous substitutions introduced into human
CFTR exons 10 and 13 have a deleterious effect on splicing
(previously known as exons 9 and 12 [9,14]), confirming that pre-
mRNA splicing depends on the regulatory information provided at
the nucleotide level. Nevertheless, most patient-derived synony-
mous variants have not been systematically studied.
We searched for all reported variants located at synonymous
codon positions in CFTR and used two computational tools, the
Skippy web server [15] and SplicePort [16], to predict their effect
on CFTR pre-mRNA splicing. Using a minigene splicing assay,
which has been validated as a method to study CFTR splicing
mutations [17], we identified two synonymous mutations that
cause aberrant CFTR splicing through activation of cryptic exonic
SSs for CFTR exons 8 and 22.
2. Methods
2.1. Exon numbering system
Exon numbering is taken from the 27-exon designation used
in the Cystic Fibrosis Mutation Database [4].
2.2. Variant data
Synonymous substitutions in the CFTR gene were identified
from dbSNP (v130) and the CFMutationDatabase. For the former,
we used the SNP mapping to the UCSC hg18 assembly of the
human genome (http://hgdownload.cse.ucsc.edu/goldenPath/
hg18/database/snp130.txt.gz), and found 43 SNPs corresponding
to synonymous changes in the CFTR gene. Additionally, we
searched the CF Mutations database (http://www.genet.sickkids.
on.ca/) for exonic mutations (a total of 1,444 entries were
retrieved), from which we selected point mutations (1065 entries)
that corresponded to synonymous changes (a total of 94 entries). In
total, we found 99 unique synonymous variants from the two
databases (Table S1), three of which (c.1036CNT, c.2245CNT,
c.3472CNA) occur at first codon positions.
2.3. Computational analysis of SNP impact on CFTR splicing
All synonymous substitutions were analyzed using the Skippy
web server [15]. Given mutation types and positions within exons,
this tool evaluates several aspects of exonic splicing regulatoryfeatures that could cause aberrant splicing, such as loss of exonic
splicing enhancers (ESEs) and gain of exonic splicing silencers
(ESSs). Skippy also evaluates the possibility of cryptic exonic SS
activation using MaxEnt scores [18], which evaluate SS strength.
We compared the score difference for “AG” and “GT” di-
nucleotides within three and four nucleotides, respectively, of each
variant. The SplicePort tool [16] evaluates the strength of SS based
on sequence features located within 80 bps of each side of
consensus “AG” and “GT” dinucleotides. We evaluated the impact
of each variant on the strength of consensus dinucleotides by
calculating the difference in SplicePort scores corresponding to
reference and variant alleles. This approach has the advantage of
linking variants located deep within exons to the performance of
the donor or acceptor sites individually, or simultaneously when
exons are shorter than 160 bps. Additionally, we checked whether
the mutations created novel consensus “AG” and/or “GT”
dinucleotide, and evaluated their strength using SplicePort.
2.4. Selection of variants for experimental testing
Based on our Skippy analysis of the 99 synonymous CFTR
variants, we chose five for experimental testing. Three variants
(rs1800083, rs1800084, rs1800122; variants 2, 3 and 5, respec-
tively) have log-odds ratio (LOR) scores higher than the threshold
value of 1.20 (Table 1), which indicates that they are statistically
more similar to known splice-affecting variants (SAVs) than to
neutral human polymorphisms that do not affect splicing (hSNPs).
The threshold represents the minimal score for predicting variant
involvement in exon skipping [15]. We also chose to test
rs1800105 (variant 4) because it scored well for activating a
cryptic acceptor SSs in a Skippy analysis. In this case, the change
in theMaxEnt 3′ SS score between the mutant and reference alleles
(Δ3′SS) is higher than the suggested threshold of 1.0 (Table 2)
[15]. Rs35033453 (variant 1; Table 1) served as a test of a negative
prediction, since it did not meet the threshold LOR score despite
having a large loss of ESEs in the Skippy analysis (Table 2).
Limited information is available for these variants. For
example, frequency information for variant 1 comes from
dbSNP, which reports it in one out of 28 chromosomes sampled
Table 2
Skippy output for the five variants chosen for experimental testing.
Variant
number
Number
of ESE
losses
Number
of ESE
gains
Number
of ESS
gains
LOR
score
Exonic environment⁎ Intronic ESS density⁎ Enhancement
of cryptic 3′
splice signal
(Δ3′SS)
Score of
cryptic 3′
splice
signal
(MaxEnt)
Score of
exon 3′
SS
(MaxEnt)
ESE density ESS density Upstream Downstream
1 3 0 0 0.749 N=1 0 N=1 0 NA NA 10.26
2 2 0 3 3.152 0 0 0 0 NA NA 8.16
3 1 0 2 2.006 0 0 0 0 0.45999 8.92 8.16
4 0 0 0 −1.284 0 N=2 N=1 N=2 1.16 4.62 6.71
5 4 0 0 1.36 N=1 N=2 N=1 0 NA NA 9.83
Notes: *Skippy reports densities of exonic and intronic ESEs and ESSs as standard deviations from mean values observed for variants that do not affect splicing
(hSNPs). Δ3′SS scores represent the difference between the original splice site score and the cryptic spice site score.
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reported in one individual [19], but no further information is
currently available (Edkins, pers. comm. 2011). Variant 3 was
found in one out of 150 chromosomes sampled, in a relative of
a CF patient [20], as well as in a control patient of a more recent
survey [21]. Variant 4 was found once among 60 chromosomes
sampled, in a CF patient with two other debilitating mutations
[22]. Variant 5 is a rare allele found in one out of 274
chromosomes sampled from CF patients from Southern France
[23].2.5. Minigene constructs
Reference and variant allele sequences were synthesized by
GenScript (Piscataway, NJ) and inserted into a PUC19 plasmid.
Constructs included the exon of interest with at least 51 bps of
flanking intronic sequences (Table 3). These sequences were
transferred into the Invitrogen TOPO-TA cloning plasmid,
pCR®8, after PCR amplification of the insert region using 30
second annealing and extension cycles and 55 °C annealing
temperature (primer sequences provided in Table 3). The
completed constructs were verified by digestion with EcoRI and
DNA sequencing. The CFTR regions were subsequently trans-
ferred into the pDESTsplice minigene splicing vector [24] using
the second step of the Gateway cloning (known as an “LR”
reaction) according to manufacturer's instructions (Invitrogen). InTable 3
Summary information for the source of genomic sequences (exons and their flanks)
Variant Exon
size
(bps)
5′
Flank
(bps)
3′
Flank
(bps)
Total
size
(bps)
Genomic coo
Start
1 164 61 57 282 116,962,478
2 247 61 83 391 116,967,329
3 247 61 83 391 116,967,329
4 129 71 66 266 117,022,149
5 249 51 51 351 117,054,761the pDESTsplice vector, target exons lie between constitutively
expressed exons from the rat insulin 2 gene. Final constructs were
verified by restriction digestion with BsrGI followed by DNA
sequencing.2.6. In vitro transfection
Using a standard protocol for transfection, 4×105 K562
cells were transfected with 0.4 μg of plasmid DNA carrying
either the reference allele or variant allele of interest. Three
replicate transfections were performed for each plasmid by
electroporation (using the Lonza 96-well Nucleofector II).
Individual transfection reactions were plated in 1 mL media in a
12 well plate. After 24 hours the three replicates were combined
for RNA harvest using the RNeasy® mini kit (Qiagen). Reverse
transcription was performed using the iScript™ cDNA
synthesis kit (Bio-Rad Laboratories). To generate cDNA,
900 ng of the RNA was used in a 20 μL iScript reaction mix
and incubated in a PCR machine under the following
conditions: 5 minutes at 25 °C, 30 minutes at 42 °C and 5
minutes at 85 °C. Variants 2 and 5 were also transfected into
IB3-1 cells. A total of 6×105 cells were transfected with 2 μg
of DNA (in triplicate) by Lipofectamine 2000 (Invitrogen, cat.
no. 11668‐500) and plated into 2 mL of medium in a 6 well
plate. After 24 hours, samples were handled the same way as
indicated for K562 cells.used in the minigene splicing assay.
rdinates (hg18) Primers
End
116,962,757 5′-TTAGTTTCTAGGGGTGGAAGATACA-3′
5′-GGGCTTTTTGAAAACATAATTTTTAA-3′
116,967,719 5′-GATCCCTGATATTTGAAAAATAAAAT-3′
5′-ACATTTTTGCAAAGTTCATTAGAACT-3′
116,967,719 5′-GATCCCTGATATTTGAAAAATAAAAT-3′
5′-ACATTTTTGCAAAGTTCATTAGAACT-3′
117,022,414 5′-TAAAAATAAAACCACAATGGTGGC-3′
5′-ATACATCCCCAAACTATCTTAATTTAA-3′
117,055,111 5′-TGAAATTGTCTGCCATTCTTAAAA-3′
5′-GATTCACTTACTGAACACAGTCTAACA-3′
Fig. 1. Summary of computational predictions for synonymous substitutions
identified in CFTR. The Venn diagram depicts counts of mutations determined
computationally to affect acceptor and donor SSs through SplicePort scoring (3′SS
and 5′SS, respectively), or to affect the splicing regulatory landscape by Skippy
(LORN1.2).Mutations found to affect splicing are shownwith a shaded background.
Variant 4 (c.2604ANG) is not included here since it does not have a high LOR score,
and does not lower scores of SSs in exon 15.Mutation c.1731CNTwas not evaluated
in this study, but was found to affect skipping by Pagani et al. [14]. ⁎The name for
this mutation was determined from its position, but is not currently found in the CF
Mutation Database.
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The cDNA containing the spliced products of the minigene
vector was amplified using PCR primers specific for the rat insulin
2 exons (5′-CCTGCTCATCCTCTGGGAGC-3′, 5′-AGGTCT-
GAAGGTCACGGGCC-3′). Conditions were set at 95 °C dena-
turation for 5 min, followed by 35 cycles of 95 °C for 1 min, 62 °C
for 1 min, and 72 °C for 1 min, with a final 72 °C hold for 5 min.
Products were visualized by gel electrophoresis on a 2% agarose
gel. Quantitation of the cDNA products was performed in parallel
using the same forward PCR primer, with an additional tag at the 5′
end with 6-carboxyfluorescein to enable measurement of differ-
ences in the size and quantity of the reference and variant minigene
products. Quantitation samples were run on the Applied
Biosystems (ABI) Prism 3100 Genetic Analyzer, which included
the use of a 36-cm capillary array and POP4 polymer. All samples
were run with the ABI internal lane size standard ROX 500, which
accurately sizes 35–500 bp fragments. Quantitation data was
analyzed using ABI GeneScan (Version 3.7 II) and Genotyper
(Version 2.5) software.
PCR products of the cDNA were subcloned using the pCR®8
TA cloning vector (Invitrogen) and sequenced to determine the
precise boundaries generated during abnormal splicing. The
sequences were verified by confirming that the spliced sequences
were flanked by rat insulin 2 exon sequences, and were mapped to
the CFTR genomic sequence using BLAT [25]. We examined the
effects of splicing mutations on the open reading frame (ORF) of
the CFTR protein using Artemis Genome Browser and Annotation
Tool [26]. Genomic nucleotide sequences (accession numbers
AC000111 andAC000061.1) were imported directly fromEMBL-
EBI using Artemis Dbfetch tool.
3. Results
3.1. Computational evaluation of variants
We first evaluated the impact of the synonymous substitutions
using the NHGRI Skippy web server. The underlying model used
by Skippy examines internal exons only, and therefore six
mutations located in the first and last exons were not evaluated.
Among the 93 variants evaluated by Skippy, 16 produced LOR
scores larger than 1.2 (Fig. 1, Tables S1, S2), suggesting that they
could severely affect the exonic regulatory landscape.
In addition to the comprehensive LOR metric, Skippy also
indicates whether variants are likely to create de novo cryptic
splice signals, which would alter the length of the original exons.
Alternative acceptor splice signals were detected in 13 cases, with
five meeting the Skippy threshold score of a Δ3′SS greater than
1.0 (Tables S1, S2). Alternative cryptic donor splice signals with
Δ5′SS scores greater than 1.0 were identified in two additional
variants (Tables S1, S2). We also verified the activation of cryptic
SSs using the SplicePort scoring scheme. Only two and six
variants increased the score of alternative acceptor and donor SSs,
respectively, beyond the scores of constitutive SSs (Table S1).
We also used SplicePort to evaluate the impact of variants on
the strength of the constitutive SSs and found several variants that
decreased their scores (Tables S1, S3). Specifically, 21 variantsaffected acceptor SSs (Figure S1, Table S1) and 26 affected donor
SSs (Figure S2, Table S1). As anticipated, the mutations with the
largest effect on SS scores were those located at the exon
boundaries. We confirmed 5 known mutations at donor SSs
(Figure S2, Table S1) and found two additional examples
(c.1209GNA and c.1584GNA) [27,28] not reported in the CFTR
database to affect splicing.
Overall, we concluded that 46 variants could have a detrimental
effect on splicing (Fig. 1). Of these, 14 appear to interfere with
splicing by a dual mechanism (e.g. either affecting both acceptor
and donor SSs or by affecting one SSs along with internal ESRs).
Mutations chosen for experimental testing represent these
mechanisms for interference with CFTR splicing. For example,
variants 2, 3 and 5 alter the ESR environment, and variant 4 scores
well for activating a cryptic acceptor splice signal while also
affecting the ESR environment (see Methods, Table 1).3.2. Minigene splicing assay results
Functional consequences of the five selected variants (Table 1)
were tested using a minigene splicing assay. Reference and variant
alleles were cloned into the pDESTsplice vector and transiently
transfected into K562 cells (see Methods). Evidence of altered
splicing was identified in two of the five variants (variants 2 and 5;
Fig. 2A), and results were replicated in IB3-1 cells (a mutantCFTR
lung epithelial cell line with the CFTR genotype of D508/
W1282X) (Fig. 2B). In the case of variant 2 the strongest band
resulted from use of a cryptic splice site that shortened the 440-bp
product by 71 bp (Fig. 2). Additionally, full exon skipping
occurred 2-times more frequently than for the reference allele
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Fig. 2. Experimental assessment of splicing interference by five synonymous substitutions. A) Gel with splicing products collected following transient transfection
into K562 cells. For each variant [1–5], constructs with the reference (R) and variant (V) alleles were analyzed separately. White arrows point to bands that indicate
differential splicing; numbers correspond to band sizes. Results of quantitation with fluorescent labeled PCR primers (conducted in a separate experiment) are shown
for variants 2 and 5, revealing different splicing patterns between reference and variant alleles. Exon+ and Exon− correspond to normal splicing (higher band) and
cryptic splicing (lower band), respectively. B) Results for variants 2 and 5 were replicated in IB3-1 cells, a cell line more relevant for the phenotype of CF patients.
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reference allele to a product 200 bps smaller (Fig. 2).
The remaining three variants showed virtually unaltered
splicing patterns between reference and variant alleles,
including full length exon skipping. Moreover, variant 1
showed substantial exon inclusion, which is consistent with
having an LOR score lower than the threshold of 1.2 (Fig. 2).
The fluorescent quantitation also indicated that exon inclusion
occurred at a slightly higher rate for the variant than for the
reference allele (RFUs 7039 and 4984, respectively).A
B
Fig. 3. Schematic representation of splicing aberrations introduced by variants 2 and
allele (splicing pattern shown above by dashed lines). When the variant “T” allele is
exon (splicing pattern shown below by dotted lines). B) In the case of variant 5 (c.3
introns are not shown to scale, whereas the middle exon is shown to scale. Numbers
background.3.3. Effect of mutations on reading frame
The splicing boundaries of each exon were determined
through sequencing the PCR product corresponding to the band
size of interest and identifying the vector-derived sequence that
originated from the rat insulin 2 gene. In the case of variant 2,
71 bps were eliminated from the 5′ end of the CFTR exon
8 (Fig. 3A). This would cause a shift in the ORF, which in turn
would cause truncation of the protein through a premature
STOP codon further downstream in exon 9 (TAA at chr7:5. A) Exon 8, in which variant 2 is located, is fully spliced with the reference
present at exon position 46, a total of 71 bps are skipped from the 5′ end of the
594GNT), 200 bps are skipped from the 3′ end of exon 22. Flanking exons and
indicate size in bps of each section. The skipped region is shown with shaded
516 A. Scott et al. / Journal of Cystic Fibrosis 11 (2012) 511–517116,969,329–116,969,331). In the case of variant 5, 200 bps
were eliminated from the 3′ end of exon 22 (Fig. 3B). Similarly
to the case of variant 2, the shift in ORF predicted by this
deletion would introduce an early STOP codon (TGA at chr7:
117,069,799–117,069,801), which would cause truncation of
the protein.
4. Conclusions
Our analyses demonstrate the dramatic effects of two seemingly
innocuous SNPs on splicing in the CFTR gene. We have shown
that synonymous substitutions in CFTR exons 8 (variant 2,
c.915CNT) and 22 (variant 5, c.3594GNT) are capable of altering
normal splicing patterns through ectopic SS activation in vitro and
thus would represent mutations, not neutral polymorphisms, as
listed in the dbSNP repository [29]. Note that although all variants,
except variant 1, are included in the CF Mutation Database
(Table 1), they are described as neutral sequence variations, which
may inaccurately describe variants 2 and 5. While the use of an in
vitro minigene assay strongly suggests that these variants alter
splicing, only in vivo assessment can validate the splicing outcome.
The presence of other unknown variants in those genetic
haplotypes could also influence the splicing outcome positively
or negatively. RNA samples carrying these variants were not
available for further testing.
Variant 2 enabled use of an ectopic SS, although some normal
product was also produced. Notably, variant 2 coincided with the
creation of three ESSs, a feature which we have previously
observed at sites of de novo ectopic splicing [15]. Moreover,
SplicePort reported a reduced score of the acceptor SS due to the
variant. Our manual examination of the sequence indicates that the
mutation creates a new consensus branch point sequence YTNAY
(where Y=pyrimidine, N=any nucleotide) [30], for which the
CNT substitution introduces a T residue at the second position of
the consensus sequence. Consistent with observed branch point
locations in humans [30], the cryptic branch point ‘A’ residue is
located 24 bps upstream from the ectopic acceptor SS. These
observations suggest that the de novo branch point sequence can
outcompete the original branch point sequence. This conclusion is
supported by the use of the alternative acceptor SS (at exon
position 72), whose SplicePort score increases from −0.5 to −0.29
in the presence of variant 2, while remaining lower than the
constitutive acceptor SS (that decreases from 0.4 to 0.03) and
another alternative acceptor SS (at exon position 120), whose
SplicePort score increases from −0.21 to −0.05.
Variant 5 also demonstrated activation of a cryptic SS, though it
only eliminated ESEs without creating new ESSs. This example
highlights the importance of complementary analyses by multiple
computational tools, such as Skippy and SplicePort. Because the
mutation happened in the middle of this 249-bp exon, SplicePort
could not evaluate the effect on the reference SSs, being more than
80 bps away from either junction, while Skippy could assess the
loss of ESEs and gain of ESSs. However, SplicePort additionally
revealed that the alternative donor signal had the highest score
(−0.28) among any SS signals affected by the variant. The score of
the alternative signal was higher than that of the original reference
SS (−0.64), indicating that the loss of four ESEs was the crucialevent in the shift of SS usage. This mutation is located in the M11
region of the MSD2 transmembrane domain of the CFTR protein.
Any product carrying the deletion would lack the C-terminal
nuclear binding domain. Unfortunately, the effect of the mutation
in vivo could not be tested due to death of the patient in infancy [23]
(des Georges, pers. comm. 2011).
In this analysis we tested variant 1 despite the fact that it fell
below the threshold LOR score recommended for Skippy
assessment because the loss of three ESE sites provided a
reasonable hypothesis for further examination. Nevertheless, the
in vitro splicing of the variant allele was consistent with our
predictions of no exon skipping. Moreover, our negative result
from variant 4 might be explained by results from our previous
work, which showed that ectopic SSs are predominantly located in
the half of the exon closest to the natural SS they replace [15]. In
the case of variant 4, the predicted ectopic acceptor SS occurs in the
unfavorable 3′ half of the exon. Furthermore, in agreement with the
experimental result, the SplicePort score for the alternative splice
signal remained much lower than the reference SS. Given that the
Skippy and Spliceport tools utilize different models of SSs (i.e.,
MaxEnt scores at the SS core, or 160 bp around the SS,
respectively) examination by more than one tool may be important
for prioritization purposes.
All variants characterized in this study are likely to be
overlooked by classical methods since their status as synonymous
substitutions does not cause a change in the amino acid sequence.
Additionally, the occurrence of these synonymous variants in the
third position of the codon further supports an a priori conclusion
of neutral substitutions. Nevertheless, we examined sequence
conservation, which often indicates regulatory information [31] in
intronic [32] and exonic splicing elements. At the single nucleotide
level, reference alleles for variants 2 and 5 did not demonstrate a
strong correlation between sequence conservation and functional
impact. Although variant 1 was conserved, its effect of slightly
increasing the splicing efficiency contradicts the predicted
consequence of losing a conserved base. The variant 1 substitution
is used in several species, includingM. domestica,G. gallus, andX.
tropicalis, providing evidence that it is not detrimental in vivo.
Variant 3, which did not show splicing interference, also shows
conservation across mammals. These results imply that conserva-
tion at single base resolution is not necessarily indicative of
constraints applied to splicing regulation, and that variants
replacing conserved positions will not a priori have a negative
effect. This conclusion is supported by the example of c.1731CNT,
which causes exon skipping [14]. Despite this, the “T” variant,
when present in rodents, is associated with 100% exon inclusion.
This example underlines the fact that splicing regulation is done
through a complex environment (e.g. rodents have additional
sequence differences from humans which may compensate in
distinct ways). Therefore the role of single nucleotides should only
be considered in their specific environments. We also looked at
negative selection measured over the neighborhood of a variant
using the regulatory constraint (RC) model [15] implemented in
Skippy. However we found no data supporting regulatory
constraint at variants 2 and 5. Thus sequence conservation, while
often used to implicate splicing elements, does not provide
predictive strength in these cases.
517A. Scott et al. / Journal of Cystic Fibrosis 11 (2012) 511–517The findings in this study indicate that synonymous sub-
stitutions can have a dramatic effect on splicing, and thus should be
evaluated in functional studies. Because synonymous and non-
synonymous substitutions can have consequences extending
beyond the amino acid sequence, mutation analysis should
routinely include the use of bioinformatics tools to evaluate the
effects of sequence variations on splicing. It should be noted that
the tools are useful for prioritization of variants; however due to the
complexity of splicing events, they are prone to false positive and
false negative predictions and necessitate experimental testing.
Results obtained from mini-gene splicing assays often recapitulate
the in vivo situation and provide justification for further
experimental examination of patient samples, when available.
Our findings provide evidence that pre-mRNA splicing ought to be
evaluated in CF genomes where a second mutation eludes
detection. In clinical diagnostics, synonymous substitutions should
not be regarded as functionally neutral and may be significant
contributors in compound heterozygous diseases. Proper classifi-
cation of suchmutations will be helpful in future assessment of CF,
in therapeutic targeting, and to specifically address molecular
mechanisms of disease.
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